Cancer Research and Treatment

Case Report

Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis: Won-Young Park, Han-Jo Kim, Kyoungha Kim, Sang-Byung Bae, Namsu Lee, Kyu-Taek Lee, Jong-Ho Won, Hee-Sook Park, Sang-Cheol Lee; Cancer Res Treat. 2016;48(2):843-847. Published online March 2, 2015; DOI: https://doi.org/10.4143/crt.2014.234

Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis.

Citations

Citations to this article as recorded by

The research progress on meningeal metastasis in solid tumors
Yi Yue, Yuqing Ren, Chunya Lu, Nan Jiang, Sihui Wang, Junkai Fu, Mengrui Kong, Guojun Zhang
Discover Oncology.2025;[Epub] CrossRef
An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?
Mainak Bardhan, Debankur Dey, Vinay Suresh, Binish Javed, Vyshak Alva Venur, Neha Joe, Ritvika Kalidindi, Ahmad Ozair, Marium Khan, Reshma Mahtani, Simon Lo, Yazmin Odia, Manmeet S. Ahluwalia
Expert Review of Neurotherapeutics.2024; 24(1): 77. CrossRef
Intrathecal Trastuzumab for HER2-Positive Cancer of Unknown Primary Leptomeningeal Metastasis: A Case Report
Kohei Oka, Shun Futamura, Taishi Harada
Cureus.2024;[Epub] CrossRef
A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers
Fatemeh Jafari, Mohammad Moeini Nodeh, Hesamoddin Hosseinjani, Hamed Baharara, Sajad Azad, Omid Arasteh, Thomas P. Johnston, Amirhossein Sahebkar
Current Medicinal Chemistry.2024; 31(19): 2732. CrossRef
Leptomeningeal Carcinomatosis from Solid Tumor Malignancies: Treatment Strategies and Biomarkers
Rachna Malani, Ankush Bhatia, Allison Betof Warner, Jonathan T. Yang
Seminars in Neurology.2023; 43(06): 859. CrossRef
Leptomeningeal metastases: the future is now
Rimas V. Lukas, Jigisha P. Thakkar, Massimo Cristofanilli, Sunandana Chandra, Jeffrey A. Sosman, Jyoti D. Patel, Priya Kumthekar, Roger Stupp, Maciej S. Lesniak
Journal of Neuro-Oncology.2022; 156(3): 443. CrossRef
Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
Yajing Chi, Mao Shang, Liang Xu, Heyi Gong, Rongjie Tao, Lihua Song, Baoxuan Zhang, Sha Yin, Binbin Cong, Huihui Li
Frontiers in Oncology.2022;[Epub] CrossRef
Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression
Flora Zagouri, Panagiotis Zoumpourlis, Emilie Le Rhun, Rupert Bartsch, Eleni Zografos, Kleoniki Apostolidou, Meletios-Athanasios Dimopoulos, Matthias Preusser
Cancer Treatment Reviews.2020; 88: 102046. CrossRef
Leptomeningeal carcinomatosis in patients with breast cancer
Maria Alice Franzoi, Gabriel N. Hortobagyi
Critical Reviews in Oncology/Hematology.2019; 135: 85. CrossRef
Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy
Nicholas B. Figura, Victoria T. Rizk, Homan Mohammadi, Brittany Evernden, Sepideh Mokhtari, H. Michael Yu, Timothy J. Robinson, Arnold B. Etame, Nam D. Tran, James Liu, Iman Washington, Roberto Diaz, Brian J. Czerniecki, Hatem Soliman, Hyo S. Han, Solmaz
Breast Cancer Research and Treatment.2019; 175(3): 781. CrossRef
Breast leptomeningeal disease: a review of current practices and updates on management
Nicholas B. Figura, Victoria T. Rizk, Avan J. Armaghani, John A. Arrington, Arnold B. Etame, Hyo S. Han, Brian J. Czerniecki, Peter A. Forsyth, Kamran A. Ahmed
Breast Cancer Research and Treatment.2019; 177(2): 277. CrossRef
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
Kelsey M Bowman, Priya Kumthekar
Future Oncology.2018; 14(4): 391. CrossRef
Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience
Nicholas B. Figura, Wendy Long, Michael Yu, Timothy J. Robinson, Sepideh Mokhtari, Arnold B. Etame, Nam D. Tran, Roberto Diaz, Hatem Soliman, Heather S. Han, Solmaz Sahebjam, Peter A. Forsyth, Kamran A. Ahmed
Breast Cancer Research and Treatment.2018; 169(2): 391. CrossRef
Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches
Niyanta N. Kumar, Michelle E. Pizzo, Geetika Nehra, Brynna Wilken-Resman, Sam Boroumand, Robert G. Thorne
Bioconjugate Chemistry.2018; 29(12): 3937. CrossRef
Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era
J. Remon, E. Le Rhun, B. Besse
Cancer Treatment Reviews.2017; 53: 128. CrossRef
Current challenges in the management of breast cancer brain metastases
Ciara C. O’Sullivan, Nicole N. Davarpanah, Jame Abraham, Susan E. Bates
Seminars in Oncology.2017; 44(2): 85. CrossRef
Leptomeningeal disease: current diagnostic and therapeutic strategies
Gautam Nayar, Tiffany Ejikeme, Pakawat Chongsathidkiet, Aladine A. Elsamadicy, Kimberly L. Blackwell, Jeffrey M. Clarke, Shivanand P. Lad, Peter E. Fecci
Oncotarget.2017; 8(42): 73312. CrossRef
Leptomeningeal metastases of solid cancer
Emilie Le Rhun, Evanthia Galanis
Current Opinion in Neurology.2016; 29(6): 797. CrossRef
Metastatic breast cancer: The Odyssey of personalization
A. Sonnenblick, N. Pondé, M. Piccart
Molecular Oncology.2016; 10(8): 1147. CrossRef
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Eleonora Teplinsky, Francisco J. Esteva
Current Oncology Reports.2015;[Epub] CrossRef

16,585 View
193 Download
21 Web of Science
20 Crossref

Original Articles

Phase II Study of Docetaxel and Cisplatin as First-line Chemotherapy in Patients with Recurrent or Metastatic Gastric Cance: Kyung-Ha Kim, Ki-Ju Jeung, Hyun-Jung Kim, Sang-Byung Bae, Chan-Kyu Kim, Nam-Su Lee, Kyu-Taek Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park; Cancer Res Treat. 2007;39(2):49-53. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.49

Abstract PDF PubReader ePub

Purpose

Palliative chemotherapy for patients with recurrent or metastatic gastric cancer has been shown to have a survival benefit. Docetaxel monotherapy has achieved appreciable results for treating gastric cancer. We investigated the clinical efficacy and feasibility of a docetaxel and cisplatin combination regimen for patients suffering with recurrent or metastatic gastric cancer.

Materials and Methods

Patients with histologically proven, bidimensionally measurable lesions of recurrent or metastatic gastric cancer, and they had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 and no prior palliative chemotherapy were eligible for this study. The combination chemotherapy regimen consisted of docetaxel 75 mg/m² plus cisplatin 75 mg/m² on day 1, and this was repeated every 3 weeks until disease progression.

Results

32 patients were enrolled from 2002 to 2005. The objective response rate was 31.3% (95% confidence interval (CI): 14.2~48.2%) with no CR. The disease control rate was 59.4%. At a median follow up of 38.9 months, the median overall survival was 7.4 months (95% CI: 6.3~8.5). The median time to progression was 4.7 months (95% CI: 3.1~6.3). During a total of 106 cycles, grade 3 or 4 hematological toxicities were observed as follows: neutropenia (39 of 106 cycles) and anemia (3 of 106 cycles). The grade 3 or 4 non-hematological toxicities included anorexia (18.9%) and nausea/vomiting (21.7%).

Conclusion

Docetaxel and cisplatin combination chemotherapy showed promising anti-tumor activity and this was well tolerated as a first-line treatment for patients with recurrent or metastatic gastric cancer. Further large, randomized phase III studies are warranted.

Citations

Citations to this article as recorded by

CYTOTOXIC EFFECTS OF ARIPIPRAZOLE ON MKN45 AND NIH3T3 CELL LINES AND GENOTOXIC EFFECTS ON HUMAN PERIPHERAL BLOOD LYMPHOCYTES
Mohammad SHOKRZADEH, Abbas MOHAMMADPOUR, Mona MODANLOO, Melika HASSANI, Nasrin Ghassemi BARGHI, Parisa NIROOMAND
Arquivos de Gastroenterologia.2019; 56(2): 155. CrossRef
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma
Ilkay Tugba Unek, Tulay Akman, Ilhan Oztop, Olcun Umit Unal, Tarik Salman, Ugur Yilmaz
Gastric Cancer.2013; 16(3): 428. CrossRef
A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
Hei‐Cheul Jeung, Sun Young Rha, Chong Kun Im, Sang Joon Shin, Joong Bae Ahn, Woo Ick Yang, Jae Kyung Roh, Sung Hoon Noh, Hyun Cheol Chung
Cancer.2011; 117(10): 2050. CrossRef
Comparison of Cisplatin-5-Fluorouracil-Folinic Acid versus Modified Docetaxel-Cisplatin-5-Fluorouracil Regimens in the First-Line Treatment of Metastatic Gastric Cancer
F. Tugba Kos, Dogan Uncu, Nuriye Özdemir, Burcin Budakoglu, Hatice Odabaş, Hüseyin Abali, Berna Oksuzoglu, Sercan Aksoy, Nurullah Zengin
Chemotherapy.2011; 57(3): 230. CrossRef

8,939 View
52 Download
4 Crossref

A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer: Sang-Byung Bae, Nam-Su Lee, Han-Jo Kim, Kyoung-Ha Kim, Hyun-Jung Kim, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park; Cancer Res Treat. 2006;38(2):72-77. Published online April 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.2.72

Abstract PDF PubReader ePub

Purpose

We prospectively conducted a non-randomized phase II trial to evaluate the efficacy and safety of combination irinotecan, leucovorin (LV) and 5-fluorouracil (FU) as a first-line regimen for treating patients with previously untreated advanced colorectal cancer (CRC).

Materials and Methods

Twenty-six previously untreated patients with advanced, recurrent or metastatic CRC were enrolled in this study. The patients received either irinotecan 180 mg/m² on day 1 with LV bolus of 200 mg/m² and FU bolus of 400 mg/m², and this was followed by FU continuous infusion of 600 mg/m² on day 1 and day 2 (the FOLFIRI regimen), or they were treated with LV bolus of 400 mg/m² and FU bolus of 400 mg/m² followed by FU continuous infusion of 2,400 mg/m² for 46 hours (the simplified FOLFIRI regimen), and these treatments were repeated every 2 weeks until disease progression.

Results

The objective response rate was 23.1% (6/26) respectively, for both treatments. The median time to progression was 5.3 months (range: 0.4~19.9), and the overall survival was 11.2 months (range: 0.5~52.3). The prognostic factor for longer survival was the Eastern Cooperative Oncology Group (ECOG) performance status (PS). The non-hematological toxicities were similar for both treatment groups, with more frequent grade ≥3 neutropenia being noted for the simplified FOLFIRI regimen.

Conclusion

The biweekly irinotecan based regimen was demonstrated to have a moderate antitumor activity with acceptable toxicity profiles, and the ECOG PS was the independent prognostic factor.

Citations

Citations to this article as recorded by

Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
Louise André, Gabriel Antherieu, Amélie Boinet, Judith Bret, Thomas Gilbert, Rabia Boulahssass, Claire Falandry
Cancers.2022; 14(10): 2470. CrossRef
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab
B. Budai, T. Nagy, I. Láng, E. Hitre
Angiogenesis.2013; 16(1): 113. CrossRef
Successful Treatment of Small-Cell Lung Cancer With Irinotecan in a Hemodialysis Patient With End-Stage Renal Disease
Dong Min Kim, Hyun Lee Kim, Choon Hae Chung, Chi Young Park
The Korean journal of internal medicine.2009; 24(1): 73. CrossRef

12,099 View
68 Download
3 Crossref

Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer: Nam-Su Lee, Hee-Sook Park, Jong-Ho Won, Dae-Sik Hong, Su-Taek Uh, Sang-Jae Lee, Joo-Hang Kim, Se-Kyu Kim, Myung-Ju Ahn, Jung-Hye Choi, Suk-Chul Yang, Jung-Ae Lee, Keun-Seok Lee, Chang-Yeol Yim, Yong-Chul Lee, Chul-Soo Kim, Moon-Hee Lee, Kab-Do Jung, Hanlim Moon, Yl-Sub Lee; Cancer Res Treat. 2005;37(6):332-338. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.332

Abstract PDF PubReader ePub

Purpose

We prospectively conducted a multi-center, open-label, randomized phase II trial to compare the efficacy and safety of docetaxel plus cisplatin (DC) and etoposide plus cisplatin (EC) for treating advanced stage non-small cell lung cancer (NSCLC).

Materials and Methods

Seventy-eight previously untreated patients with locally advanced, recurrent or metastatic NSCLC were enrolled in this study. The patients received cisplatin 75 mg/m² on day 1 and either docetaxel 75 mg/m² on day 1 or etoposide 100 mg/m² on days 1 to 3 in the DC or EC arm, respectively, every 3 weeks.

Results

The objective response rate was 39.4% (15/38) and 18.4% (7/38) (p=0.023) in the DC and EC arms, respectively. The median time to progression (TTP) was 5.9 and 2.7 months (p=0.119), and the overall survival was 12.1 and 8.7 months (p=0.168) in the DC and EC arms, respectively. The prognostic factors for longer survival were an earlier disease stage (stage III, p=0.0095), the responders to DC (p=0.0174) and the adenocarcinoma histology (p=0.0454). The grades 3 and 4 toxicities were similar in both arms, with more febrile neutropenia (7.9% vs. 0%) and fatigue (7.9% vs. 0%) being noted in the DC arm.

Conclusion

DC offered a superior overall response rate than does EC, along with tolerable toxicity profiles, although the DC drug combination did not show significantly improved survival and TTP.

Citations

Citations to this article as recorded by

Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis
Sarah Goring, Nebibe Varol, Nathalie Waser, Evan Popoff, Greta Lozano-Ortega, Adam Lee, Yong Yuan, Laura Eccles, Phuong Tran, John R. Penrod
Lung Cancer.2022; 170: 122. CrossRef

9,126 View
67 Download
1 Crossref

Combination of Gemcitabine and Cisplatin as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: Nam-Su Lee, Jae-Ho Byun, Sang-Byung Bae, Chan-Kyu Kim, Kyu-Taeg Lee, Sung-Kyu Park, Jong-Ho Won, Dae-Sik Hong, Hee-Sook Park; Cancer Res Treat. 2004;36(3):173-177. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.173

Abstract PDF PubReader ePub

Purpose

The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) is extremely poor. Many prospective randomized trials on patients with advanced NSCLC suggested systemic chemotherapy improves both the survival and quality of life. A phase II trial was conducted to evaluate the efficacy and safety profile of the combination chemotherapy of gemcitabine and cisplatin in advanced NSCLC.

Materials and Methods

Forty-four patients with locally advanced or metastatic NSCLC were enrolled. The patients received a cisplatin, 75 mg/m², infusion over 30 minutes on days 1, followed by a gemcitabine, 1,250 mg/m², infusion over 30 minutes on days 1 and 8 every 3 weeks.

Results

The median age of the patients was 64 years (range: 27~75). Forty-one patients were assessable for response and toxicity analyses. The overall response rate was 53.6%, but with no complete remissions. The median time to progression was 5.6 months (range: 1~15.4). The median survival was 14.2 months (95% confidence interval (CI), 13.8~22.5). A total of 179 cycles were administered, with a median of 4 cycles of chemotherapy, ranging from 2 to 9 cycles. The most common hematological toxicities were NCI grades 3/4 neutropenia (24%) and thrombocytopenia (7.8%). The most common non-hematological toxicity was fatigue (42.4%). There were no life-threatening toxicity or treatment related mortalities. The median duration of follow up was 9.4 months, ranging from 1.6 to 30.3 months.

Conclusion

In this trial, the combination of gemcitabine and cisplatin showed significant activity, with acceptable and manageable toxicities as a first-line regimen for patients with advanced NSCLC.

Citations

Citations to this article as recorded by

Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells
Jeong-Hun Lee, Kyung-Sook Chung, Hwi-Ho Lee, Dohyeong Ko, Minji Kang, Ho Yoo, JooHoon Ahn, Jae Yeol Lee, Kyung-Tae Lee
Biomedicine & Pharmacotherapy.2021; 142: 111961. CrossRef
Chemotherapy-Induced Myopathy: The Dark Side of the Cachexia Sphere
Dean G. Campelj, Craig A. Goodman, Emma Rybalka
Cancers.2021; 13(14): 3615. CrossRef
New Strategies for Safe Cancer Therapy Using Electrospun Nanofibers: A Short Review
Mohsen Doostmohammadi, Hamid Forootanfar, Seeram Ramakrishna
Mini-Reviews in Medicinal Chemistry.2020; 20(13): 1272. CrossRef
Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer
Louis T. Curtis, Victor H. van Berkel, Hermann B. Frieboes
Journal of Theoretical Biology.2018; 448: 38. CrossRef
Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials
Zheng Xiao, Chengqiong Wang, Ling Chen, Xuemei Tang, Lianhong Li, Nana Li, Jing Li, Qihai Gong, Fushan Tang, Jihong Feng, Xiaofei Li
Oncotarget.2017; 8(1): 1329. CrossRef
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma
Nadine Houédé, Laura Dupuy, Aude Fléchon, Philippe Beuzeboc, Gwenaëlle Gravis, Brigitte Laguerre, Christine Théodore, Stéphane Culine, Thomas Filleron, Christine Chevreau
BJU International.2016; 117(3): 444. CrossRef
Ototoxin-induced cellular damage in neuromasts disrupts lateral line function in larval zebrafish
Lauren M.J. Buck, Matthew J. Winter, William S. Redfern, Tanya T. Whitfield
Hearing Research.2012; 284(1-2): 67. CrossRef

9,074 View
45 Download
7 Crossref

Review Article

Prospect of Anticancer Therapy: Hee-Sook Park; Cancer Res Treat. 2004;36(2):100-102. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.100

PDF PubReader ePub

Citations

Citations to this article as recorded by

Diagnostic Evaluation of Respiratory Failure in Patients with Cancer
Bekele Afessa
American Journal of Respiratory and Critical Care Medicine.2010; 182(8): 992. CrossRef

7,023 View
39 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Search